

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 May 2025 (15.05.2025)



(10) International Publication Number
WO 2025/101776 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61K 31/55 (2006.01)
A61K 9/00 (2006.01) A61P 35/00 (2006.01)
A61K 9/107 (2006.01) C07D 491/08 (2006.01)
A61K 31/517 (2006.01) C07D 519/00 (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2024/054958

(22) International Filing Date:

07 November 2024 (07.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/597,325 08 November 2023 (08.11.2023) US

(71) Applicant: **KUMQUAT BIOSCIENCES INC.** [US/US];
10770 Wateridge Circle, Suite 120, San Diego, California
92121 (US).

(72) Inventors: **REN, Pingda**; 10770 Wateridge Circle, Suite
120, San Diego, California 92121 (US). **HE, Xiaohui**;
10770 Wateridge Circle, Suite 120, San Diego, California

92121 (US). **LI, Xiaoming**; 10770 Wateridge Circle, Suite
120, San Diego, California 92121 (US). **ZHAO, Siling**;
10770 Wateridge Circle, Suite 120, San Diego, California
92121 (US). **WU, Baogen**; 10770 Wateridge Circle, Suite
120, San Diego, California 92121 (US).

(74) Agent: **MALECHA, James** et al.; Wilson Sonsini
Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali-
fornia 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: HETEROCYCLES AND USES THEREOF

FIG. 1

	1	20	40	
K-Ras	mte-----	----yklvvv	gagggvgsal	tiqliqnhfv deydptieds yrkqvvidge 49
(SEQ ID No. 10)				
H-Ras	mte-----	----yklvvv	gagggvgsal	tiqliqnhfv deydptieds yrkqvvidge 49
(SEQ ID No. 11)				
N-Ras	mte-----	----yklvvv	gagggvgsal	tiqliqnhfv deydptieds yrkqvvidge 49
(SEQ ID No. 12)				
RalA	maankpkgn	slalhkvimv	gsggvgsal	tlqfmydefv edyepatkads yrkkvvldge 60
(SEQ ID No. 13)				
RalB	maankskggs	slalhkvimv	gsggvgsal	tlqfmydefv edyepatkads yrkkvvldge 60
(SEQ ID No. 14)				
	60	80	100	
K-Ras	tcldildtā	gqeysamrd qymrtg	egfl cvfainntks fedinh	lyreqikrvkdsed- 108
H-Ras	tcldildtā	gqeysamrd qymrtg	egfl cvfainntks fedinh	lyreqikrvkdsdd- 108
N-Ras	tcldildtā	gqeysamrd qymrtg	egfl cvfainntks fedinh	lyreqikrvkdsdd- 108
RalA	evqidildtā	ggedyaaaird nyfrs	gsegfl cvfsitemes faata	dfreqilrvk-eden 119
RalB	evqidildtā	ggedyaaaird nyfrs	gsegfl lvfsitehes ftata	dfreqilrvkaeedk 120

(57) Abstract: The present disclosure provides quinazoline- and azaquinazoline-based compounds and pharmaceutically acceptable salts thereof, and methods of using the same as modifiers of mutant Ras protein. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic protein.

[Continued on next page]

WO 2025/101776 A1

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*